Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amicus Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
CRANBURY, N.J. , Dec. 21, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley , Chairman and Chief Executive Officer, will present a corporate overview at the 36 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 9, 2018
View HTML
Toggle Summary Amicus Therapeutics Submits New Drug Application to U.S. FDA for Migalastat for Treatment of Fabry Disease
CRANBURY, N.J. , Dec. 14, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) to request approval of the oral precision medicine migalastat HCl ("migalastat") for the treatment of patients 16 years and
View HTML
Toggle Summary Amicus Therapeutics Announces Third Quarter 2017 Financial Results and Corporate Updates
260+ Fabry Patients on Reimbursed Galafold™ (Migalastat) and On Target to Reach 300 Patients by Year-End 2017 U.S. NDA Submission for Migalastat Planned in 4Q17 Pompe Retrospective and Prospective Data Collection Studies Initiated Additional Pompe Clinical Data to be Presented at WORLD Symposium™
View HTML
Toggle Summary Amicus Therapeutics to Announce Third Quarter 2017 Financial Results on November 8, 2017
CRANBURY, N.J. , Oct. 25, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Wednesday, November 8, 2017 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2017 .
View HTML
Toggle Summary Amicus Therapeutics Appoints Michael C. Diem, MD as Senior Vice President of Business and Corporate Development
Driven Business Executive with Strong Industry Track Record
View HTML
Toggle Summary Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at World Muscle Society
         Mean Six-Minute Walk Distance Improved in ERT-Naive Patients (+42 Meters at 6 Months, +75 Meters at 9 Months) and ERT-Switch Patients (+35 Meters at 6 Months, +37 Meters at 9 Months) Persistent & Durable Reductions in Key Disease Biomarkers Pulmonary Function Generally Improved or Remained
View HTML
Toggle Summary U.S. FDA Grants Orphan Drug Designation for ATB200/AT2221 for Pompe Disease
New Phase 1/2 Clinical Data to be Presented at World Muscle Society
View HTML
Toggle Summary Amicus Therapeutics to Present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
CRANBURY, N.J. , Sept. 20, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) announced that John F. Crowley , Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology in New
View HTML
Toggle Summary U.S. FDA Grants Fast Track Designation for Amicus Therapeutics' Migalastat for Treatment of Fabry Disease
New Drug Application Submission on Track for 4Q17
View HTML
Toggle Summary Amicus Therapeutics Announces Approval for Galafold™ (Migalastat) for Treatment of Fabry Disease in Canada
First Oral Precision Medicine for Fabry Disease with Broad Label for Fabry Patients with Amenable Genetic Mutations
View HTML